RBC Capital Markets adjusted their outlook on Morgan Stanley (NYSE:MS) shares, raising the price target from $122.00 to $142.00. The firm maintained a Sector Perform rating on the stock. The upgrade comes as Morgan Stanley's stock trades near its 52-week high of $136.

In a report released yesterday, Deane Dray from RBC Capital maintained a Hold rating on Lennox International (LII – Research Report), with a

Bonnici was a managing director at RBC and led several high-profile deals across infrastructure and technology during his tenure.

In a report released today, Sebastian Kuenne from RBC Capital maintained a Hold rating on ABB Ltd (0NX2 – Research Report), with a price target

Morgan Stanley analyst Rahul Anand maintained a Hold rating on 29metals Ltd. (29M – Research Report) today and set a price target of A$0.29.

Wall Street analysts largely maintained bullish views on IBM (NYSE:IBM) after the tech giant's fourth-quarter results and outlook surpassed expectations. Shares of IBM jumped about 9% premarket on Thursday.

RBC Capital Markets adjusted their outlook on Lennox International (NYSE:LII), a global provider of climate control solutions. Analyst Deane Dray at RBC Capital increased the price target for Lennox International to $642 from the previous target of $617,

ServiceNow (NYSE:NOW) provided solid fourth quarter results, but shares sank 12% during Thursday trading as more meaningful revenue growth looks pushed out to the second half of 2025. However, analysts find room for optimism,

Microsoft's second quarter fiscal 2025 earnings show impressive growth in AI revenue, despite slightly slower Azure growth. Read more here.

Microsoft Corporation MSFT analysts balance the positives and negatives of Azure’s weakness and strength in AI from the company’s quarterly financial results. Morgan Stanley analyst Keith Weiss maintained an Overweight rating on Microsoft and lowered the price target from $540 to $530.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $142.0 and $165.0 for Johnson & Johnson, spanning the last three months. Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

The Adam Watson-led APA is understood to be instead focusing – at this time – on organic opportunities within its existing business.